Reviewed by David Kindness
Gilbert Carrasquillo
Theranos Inc. was a consumer healthcare technology startup that closed down in 2018, after the company, its CEO Elizabeth Holmes, and former president Ramesh Balwani were indicted by the SEC for scheming to defraud investors, doctors, and patients. At one time, the company, whose leadership claimed it would revolutionize the blood-testing industry, had been not just a unicorn—a term applied to start-ups valued at $1 billion—but a decacorn, thanks to having been valued at $10 billion.
The technological breakthrough that Holmes and Balwani touted was never demonstrated, and Holmes was accused of purposefully lying to investors and patients, as well as lying about the company’s profitability. Holmes’ and Balwani’s separate fraud trials resulted in their being convicted and sentenced to prison.
Key Takeaways
- Theranos Inc. was a consumer healthcare technology startup that claimed to revolutionize the blood-testing industry.
- Theranos reportedly raised roughly $724 million of capital from venture capitalists and private investors, ultimately attaining a valuation of $10 billion.
- Theranos CEO Elizabeth Holmes claimed that the company had developed a new technology to test blood, but these claims were later discovered to be fraudulent.
- In 2018, the SEC charged Theranos, Holmes, and former President Ramesh “Sunny” Balwani with fraud. Both Holmes and Balwani were eventually imprisoned for fraud.
- By June 2016, Elizabeth Holmes’ net worth reportedly dropped from $4.5 billion to nothing.
Theranos
Theranos was a privately held healthcare technology company founded by then 19-year-old Elizabeth Holmes in 2003.
Using a “nanotainer” (a small device designed to draw, retain, and analyze a droplet of blood from a patient’s fingertip) and its proprietary “Edison” testing technology, Theranos claimed the device could run a multitude of tests on a patient’s physiology within minutes and at a fraction of the cost of current technology.
After more than 10 years of fundraising and reaching a peak valuation of roughly $10 billion, the tide started to turn in 2015 thanks to skepticism from the press.
Doubt on Viability
A New Yorker profile termed Holmes’ explanations of Theranos’ technology “comically vague,” citing as one example Holmes’ statement that “a chemistry is performed so that a chemical reaction occurs and generates a signal from the chemical interaction with the sample, which is translated into a result, which is then reviewed by certified laboratory personnel.”
Important
On Jan. 3, 2022, Theranos founder Elizabeth Holmes was found guilty of four out of 11 fraud charges.
The Wall Street Journal then followed with a highly critical report on Theranos. Based on interviews with ex-employees, the newspaper alleged rampant management incompetence and claimed that Theranos had grossly exaggerated the capabilities of its proprietary technology.
One former senior employee stated that only a small fraction of all the tests were conducted on the “Edison machines,” and the majority of tests were handled on competitors’ equipment despite Theranos’s claims to the contrary. If true, this would have been a violation of the U.S. Food and Drug Administration (FDA) rules.
Investigations
The FDA then released two reports from its ongoing investigation into Theranos. They were less than favorable and claimed that Theranos had “uncleared medical device(s),” poor records, was mishandling complaints, and had failed to conduct audits and produce supplier qualifications. In regard to an unspecified medical device, an investigator noted: “The design was not validated under actual or simulated use conditions.” Further, Theranos failed to “ensure the device conforms to defined user needs and intended uses.”
At the beginning of 2016, a letter released by the Centers for Medicare & Medicaid Services (CMS) stated that a California-based lab used by Theranos posed “immediate jeopardy” to patient health and safety. CMS gave the company 10 days to correct the deficiencies or face daily fines and/or loss of CMS approval for Medicare payments.
Charges of Fraud
After a couple of years of settled lawsuits, dissolved relationships with big partners such as Walgreens, and broken deals with the likes of Safeway, the U.S. Securities and Exchange Commission (SEC) formally charged Theranos, Holmes, and former company president Ramesh “Sunny” Balwani with “massive fraud.”
The complaint alleged that the company raised more than $700 million by deceiving investors for years about the company’s performance.
Both Theranos and Holmes agreed to settle the fraud charges pending court approval. Holmes lost control of the company, returned millions of shares, and was barred from serving as an officer or director of a public company for 10 years.
Balwani and Holmes were both sued for multiple counts of fraud. In January 2022, Holmes was convicted of three charges to commit wire fraud, and one charge of conspiracy to commit wire fraud. Later that year, Balwani was convicted of six counts of defrauding investors, four counts of defrauding patients, and two counts of conspiring to commit fraud. Balwani was sentenced to 12 years and 11 months in federal prison, while Holmes received 11 years and three months.
Note
Several works are based on Theranos and Elizabeth Holmes including: John Carrreyrou’s 2018 nonfiction book titled “Bad Blood: Secrets and Lies in a Silicon Valley Startup,” Alex Gibney’s 2019 documentary “The Inventor: Out for Blood in Silicon Valley,” and the Emmy-award winning 2022 mini-series “The Dropout,” starring Amanda Seyfried and Naveen Andrews.
A Timeline of Theranos’s Rise and Fall
2003: Nineteen-year-old Stanford chemical and electrical engineering drop-out Elizabeth Holmes founds Theranos with the aim of revolutionizing blood testing.
2004: Theranos raises $6.9 million in early funding gaining a $30 million valuation.
2007: The company’s valuation hits $197 million after it raises another $43.2 million in early-round funding.
2010: After further rounds of funding, Theranos is valued at $1 billion.
2013: After a decade of working “in the dark,” Holmes introduces Theranos to the world via press appearances and unveils a website.
2014: With over $400 million in funding, Theranos is valued at nearly $9 billion. Holmes effectively becomes a multi-billionaire thanks to her 50% stake.
December 2014: Despite her company’s hefty valuation, Holmes remains tight-lipped on how exactly Theranos’s technology works. It turns out that the technology has never been submitted for peer review in medical journals.
July 8, 2015: Capital BlueCross, a Pennsylvania insurer with 725,000 customers, chooses Theranos as its preferred lab work provider. Theranos is valued at $10 billion.
Oct. 15, 2015: The Wall Street Journal runs a scathing article criticizing Theranos.
Holmes appears on “Mad Money” and other media outlets to do damage control. She is “shocked” by the Wall Street Journal article and claims that Theranos supplied over 1,000 pages of documentation to refute the allegations. The Wall Street Journal stands by its reporting.
Oct. 16, 2015: A follow-up article in the Wall Street Journal states that Theranos was forced to suspend the use of its unapproved nanotainer for all but one type of blood test.
Oct. 27, 2015: The FDA releases two partially redacted Form 483 reports from an ongoing investigation into Theranos.
Oct. 28, 2015: Fortune reports that Theranos sought to raise an additional $200 million in Series C-3 funding just days before the initial Wall Street Journal article was published.
Nov. 10, 2015: A $350 million deal with Safeway fizzles out after Theranos failed to meet key deadlines for rollouts and Safeway executives questioned the validity of the test results.
Dec. 27, 2015: The Wall Street Journal ran another article alleging management ineptitude at Theranos and test rigging to produce better results for its Edison machines.
Jan. 27, 2016: The Centers for Medicare & Medicaid Services releases its damming report on Theranos’ California-based lab.
Jan. 28, 2016: Following the CMS report, Walgreens Boots Alliance Inc. (WBA) decides to temporarily close the Theranos Wellness Center in its Palo Alto store and suspend its use of Theranos’s Newark, California lab.
May 1, 2017: Theranos settles a lawsuit with Partner Fund Management, one of its largest investors, after the hedge fund accused the company of securities fraud. Theranos had previously settled proceedings with the Centers for Medicare & Medicaid Services and the Arizona Attorney General.
March 14, 2018: The SEC charges Theranos, its founder and CEO Elizabeth Holmes, and its former President Ramesh “Sunny” Balwani with massive fraud.
$10 billion
Theranos’s valuation at its height in 2015.
June 15, 2018: A federal grand jury indicts both Holmes and Balwani on nine counts of wire fraud and two counts of conspiracy to commit wire fraud.
The press release from the U.S. Attorney’s Office states that in order to promote Theranos, both Holmes and Balwani “engaged in a multi-million dollar scheme to defraud investors and a separate scheme to defraud doctors and patients.”
Holmes stepped down as Theranos CEO earlier in the day although she continues to be the chair of the company’s board.
September 2018: Theranos begins the process of dissolving as a company.
Jan. 3, 2022: Elizabeth Holmes is convicted on four out of 11 federal charges for conspiring to defraud investors. She is ultimately sentenced to 11 years and three months in prison.
July 7, 2022: Balwani is found guilty of all charges and ultimately sentenced to nearly 13 years in prison.
May 30, 2023: After several efforts to delay her sentence through appeals, Holmes finally reports to federal prison camp Bryan in southern Texas.
Feb. 24, 2025: Elizabeth Holmes loses her appeal in federal court to have her fraud conviction overturned.
Was Theranos Publicly Traded?
No. Theranos was a privately held corporation until it was shut down and liquidated in September 2018.
Is Theranos Still Open?
Theranos started shutting down its clinical labs and wellness centers in late 2016, finally ceasing operations in September 2018.
What Did Theranos Do Wrong?
Theranos claimed to have developed blood tests that required only small amounts of blood and devices that could quickly perform the tests. Based largely on those claims, Theranos reportedly raised roughly $724 million of capital from venture capitalists and private investors.
How Much Did Walgreens Invest in Theranos?
Walgreens reportedly invested $140 million in its partnership with Theranos.
Is Elizabeth Holmes Still Wealthy?
According to Forbes, by June 2016, Elizabeth Holmes’ net worth dropped from $4.5 billion to “nothing.” However, Holmes later married the millionaire hospitality heir Billy Evans, who went on to father her two children. Although Evans’ net worth is estimated at around $10 million, it is not clear if the couple shares their finances.
The Bottom Line
Theranos was a healthcare startup that claimed to revolutionize the blood-testing industry. However, CEO Elizabeth Holmes’ aggressive claims were later found to be fraudulent, and the company was actually fabricating results to deceive both investors and patients.
Holmes and her co-conspirator, Ramesh Balwani, were each convicted and sentenced to over a decade in federal prison. Their names, along with that of their company, have now become synonymous with fraud.